Future strategies involve interventions to modify the course of the disease using immunotherapy, gene therapy, stem cell therapy, and reducing amyloid beta accumulation.[12]  Identification of biomarkers for DLB will enable treatments to begin sooner[12] and improve the ability to select subjects and measure efficacy in clinical trials.[30]  As of  2018[update] there are no well-validated neuroimaging modalities to measure alpha-synuclein in the brains of living people, but this is an active area of research.[30]